AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to ...

Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development ...

For the biopharma industry, 2020 was many things, but for Samit Hirawat, M.D., chief medical officer of Bristol Myers Squibb, three things stand out: collaboration, adaptation and evolution.

Samit Hirawat, chief medical officer at Bristol Myers Squibb, talks about his leading role in BMS’ $300M, five-year plan to expand its efforts in health equity and his career-long commitment to ...

The approval of Biogen Inc.’s Aduhelm clarifies the U.S. Food and Drug Administration’s standard for drugs for neurodegenerative diseases, making it easier to design studies for new therapies ...

Samit Hirawat So for -- as I said earlier, for both of the studies, so CC-220, or iberdomide, we're looking at the readout of that fourth line plus population data within this year.

Samit Hirawat, the EVP of $BMY, bought 1,823 shares of the company on 02-14-2025 for an estimated $99,973. This trade was reported by Quiver Quantitative using data ...